SM
LYEL icon

SB Management’s Lyell Immunopharma LYEL Stock Holding History

SB Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-175,000
Closed -$27.1M – 21
2021
Q4 		$27.1M Hold
175,000
– – 2.68% 10
2021
Q3 		$51.8M Hold
175,000
– – 5.31% 4
2021
Q2 		$56.8M Buy
+175,000
New +$57.4M 0.67% 8

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SB Management's LYEL Position: Q1 2022 in Review

SB Management sold out of Lyell Immunopharma (LYEL) in Q1 2022, closing a stake of 175,000 shares — an estimated $27.1M sold.

SB Management first reported a position in LYEL in Q2 2021 and held it in 3 quarters. The position peaked at $56.8M in Q2 2021. 79 funds tracked by Wall St. Rank hold LYEL as of Q1 2022.

  • SB Management reported no remaining Lyell Immunopharma position as of Q1 2022 after selling out during the quarter.
  • SB Management sold 175,000 Lyell Immunopharma shares in Q1 2022, an estimated $27.1M.
  • SB Management first reported a position in Lyell Immunopharma in Q2 2021 and held it in 3 quarters.
  • SB Management's Lyell Immunopharma position peaked at $56.8M in Q2 2021.
  • 79 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2022.

Based on SB Management's 13F filing for Q1 2022, filed 16 May 2022.